[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623051":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":34,"responsibleParty":79,"collaborators":11,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":11,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":11,"enrollmentInfo":90,"targetDuration":11,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Cartesian Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Decartes-08","EXPERIMENTAL",null,[13],"Drug: Descartes-08",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Descartes-08","Autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA)",[9],{"type":26,"name":15,"description":27,"armGroupLabels":28,"otherNames":11},"OTHER","Plasma-Lyte",[15],[30],{"name":5,"role":31,"phone":32,"phoneExt":11,"email":33},"CONTACT","617-231-8102","trials@cartesiantx.com",[35,49,59,69],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":11},"University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.85311,33.78779,{"lat":47,"lon":46},{"facility":50,"status":37,"city":51,"state":52,"zip":53,"country":41,"countryCode":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":11},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":44,"coordinates":55},[56,57],-71.05977,42.35843,{"lat":57,"lon":56},{"facility":60,"status":37,"city":61,"state":62,"zip":63,"country":41,"countryCode":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":11},"University of North Carolina","Chapel Hill","North Carolina","27599",{"type":44,"coordinates":65},[66,67],-79.05584,35.9132,{"lat":67,"lon":66},{"facility":70,"status":37,"city":71,"state":72,"zip":73,"country":41,"countryCode":42,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"National Neuromuscular Research Institute","Austin","Texas","78759",{"type":44,"coordinates":75},[76,77],-97.74306,30.26715,{"lat":77,"lon":76},{"type":80,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623051","phase-2-descartes-08-in-autoantibody-myositis-100623051",false,"NCT07391605","Descartes-08 in Autoantibody Myositis","A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome","Inclusion Criteria:\n\n* Confirmed diagnosis of one of the following:\n\nDermatomyositis (DM): Probability score ≥55% on the 2017 EULAR\u002FACR (European Alliance of Associations of Rheumatology\u002F American College of Rheumatology) criteria for classification of dermatomyositis (corresponding to diagnosis of 'probable or definite' DM). OR Antisynthetase Syndrome (ASyS): Diagnosis based on ACR\u002FEULAR Classification Criteria (1).\"\n\n* Participants must have dermatomyositis or antisynthetase syndrome with muscle and\u002For skin involvement.\n* Refractory or intolerance to standard therapy.\n* Stable background immunosuppressive therapy for ≥8 weeks.\n* Adequate hematologic, renal, hepatic, and pulmonary function (SpO₂ ≥92% on room air).\n* Informed consent, compliance with visits, contraception, and vaccinations required.\n\nExclusion Criteria:\n\n* Isolated interstitial lung disease (ILD) without muscle or skin involvement\n\n  * Severe irreversible muscle damage or advanced weakness (e.g., wheelchair-bound).\n  * Interstitial lung disease (ILD) requiring oxygen, severe pulmonary impairment (FVC ≤45%, DLCO ≤40%), or pulmonary hypertension.\n  * Other inflammatory myopathies (PM, IMNM, IBM, cancer- or drug-induced myositis, overlap myositis except Sjögren's).\n  * Other severe neuromuscular, cardiac, pulmonary, or systemic autoimmune diseases requiring immunosuppression.\n  * Significant uncontrolled chronic illnesses or psychiatric conditions interfering with participation.\n  * Pregnancy or lactation.\n  * Recent use of prohibited immunosuppressants\u002Fbiologics or investigational agents (per washout periods).\n  * Live vaccination within 4 weeks.\n  * History of primary immunodeficiency, organ or bone marrow transplant.\n  * Active or uncontrolled infections: HBV, HCV, HIV, tuberculosis, or recurrent\u002Fsevere infections.","ALL","18 Years",{"count":91,"type":92},60,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).",[98],"Antisynthetase Syndrome",[100,101,102,103,104],"MYOSITIS","DESCARTES-08","MRNA CAR-T","TOTAL IMPROVEMENT SCORES","CDASI","2026-08-13",{"date":107,"type":108},"2026-08-17","ACTUAL",{"date":110,"type":108},"2026-04-28",{"date":112,"type":92},"2028-05",{"name":5,"class":6},4]